What is Mekonos?
Founded in 2017 and headquartered in California, Mekonos operates at the intersection of synthetic biology and personalized medicine. The company is dedicated to developing cutting-edge cell and gene technologies that aim to unlock new therapeutic possibilities and advance scientific research. By leveraging proprietary platforms, Mekonos is poised to make substantial contributions to the fields of biotechnology and healthcare, offering solutions that could redefine treatment paradigms for a range of diseases.
How much funding has Mekonos raised?
Mekonos has raised a total of $29.6M across 2 funding rounds:
Unspecified
$4.6M
Series A
$25M
Unspecified (2020): $4.6M with participation from Good AI Capital, Novartis AG, CRCM Ventures, Elementum Ventures, and HikeVentures
Series A (2021): $25M led by Reimagined Ventures, Fiscus Ventures, and PEAK6 Strategic Capital,
Key Investors in Mekonos
Good AI Capital
Good AI Capital is an investment firm dedicated to harnessing the power of artificial intelligence to address significant global challenges. They focus on backing visionary companies in sectors such as Healthcare, Enterprise, and Automation, aiming to generate substantial returns while making a positive impact.
CRCM Ventures
CRCM L.P. is a registered investment adviser based in San Francisco, operating since 2012. The firm provides investment advisory services to clients, focusing on tailored financial strategies. CRCM is registered with the U.S. Securities and Exchange Commission (SEC).
Reimagined Ventures
Reimagined Ventures is a venture capital firm that invests in visionary entrepreneurs across various industries, including real estate and hospitality. The firm focuses on unique, best-in-class opportunities primarily in the Chicagoland area, aiming to redefine success in hospitality and create memorable experiences.
What's next for Mekonos?
With the recent injection of major strategic investment, Mekonos is well-positioned to accelerate its research and development initiatives, scale its operations, and further commercialize its groundbreaking technologies. The company's trajectory suggests a focus on expanding its pipeline of cell and gene therapies and forging key partnerships within the pharmaceutical and biotechnology sectors. This substantial backing will likely fuel M&A activities or further R&D expansion, solidifying Mekonos's position as a leader in the rapidly evolving landscape of synthetic biology and personalized medicine.
See full Mekonos company page
